get a key
steadybase-$ company ERNA
account_id none on file
legal_name Ernexa Therapeutics Inc.
ticker ERNA
cik 748592
domain eternatx.com
entry_point_account_id none on file
name Eterna Therapeutics Inc.
exchange Nasdaq
sector Health Care
hq Cambridge, MA, United States
calls 0 filings 8 executives 4 family 0
why_nownone on file
callsnone on file
filings
supply expenses, travel expenses, stock-based compensation, allocated occupancy costs, and depreciation. 2 Other includes expenses related to insurance, occupancy expense, information technology, travel, depreciation and other miscellaneous expenses.

filing / Aug 6, 2026 / receipt

planned capital purchases or reduce expenses may be insufficient to cover shortfalls in available funds. If we require additional capital,

filing / Aug 6, 2026 / receipt

Keeley as Fractional Chief Financial Officer Effective August 10, 2026, the Company engaged Mark J. Keeley as a fractional Chief Financial Officer on a consulting basis pursuant to a Consulting Agreement dated August 5, 2026 (the "Keeley Agreement"), and designated Mr.

filing / Aug 6, 2026 / receipt

the Company may undertake to reduce planned capital purchases or reduce expenses may be insufficient to cover shortfalls in available

filing / Aug 6, 2026 / receipt

lease termination agreement was accounted for as a modification to the Manhattan Office lease rather than as a lease termination because

filing / Aug 6, 2026 / receipt

the Company did not contemporaneously terminate the Manhattan Office lease upon the February 18, 2026 modification date and had a continued

filing / Aug 6, 2026 / receipt

and cost savings for companies. Under this procedure, only one copy of the Notice of Internet Availability, and if applicable, Notice

filing / May 11, 2026 / receipt

cost reduction measures; and/or (xxiii) strategic plan development and implementation. (c) At the discretion of the Committee, the settlement of Performance Share Units or Performance Shares may be in cash, Shares of equivalent value, or in some combination thereof, as set forth in the Award Agreement.

filing / May 11, 2026 / receipt

executives
Dorothy J. Clarke director - receipt
James Bristol director - receipt
Jeff Berg Chairman - receipt
Sanjeev Luther Robert Pierce, MD - receipt
familynone on file
upcoming
2026-11-06 earnings call scheduled ir
changes
2023-12-20 President and Chief Executive Officer, appointed sec_8k
2023-11-01 director, appointed sec_8k
2023-08-31 director, appointed sec_8k
2023-08-10 President and Chief Executive Officer, departed sec_8k
2023-01-04 President and Chief Executive Officer, appointed sec_8k
2022-09-01 Chief Scientific Officer, departed sec_8k
2012-06-05 Chairman, appointed sec_8k
mcp_package_hint
steadybase-$